Proteinea

Proteinea leverages the power of artificial intelligence to revolutionize biotherapeutics discovery. Their innovative deep-learning AI models and platforms streamline protein engineering, making the process faster, safer, and more efficient. Proteinea focuses on engineering the constantregion of the protein (FC), unlocking new possibilities for treatments and biological applications. This technology empowers them to develop multiple drugs and proteins in a significantly shorter timeframe, with greater safety and efficacy.

Mahmoud Eljendy - Co-founder & CEO

Holds expertise in biotechnology and business, leading Proteinea’s vision to develop AI-powered protein engineering platforms aimed at enhancing drug discovery and creating next-generation biotherapeutics with faster, safer, and more efficient methods. He leverages deep tech innovations to transform traditional biomanufacturing approaches.

Abdulaziz Elgammal - Co-founder & CTO

Specializes in computational biology and AI integration for protein design. He directs Proteinea’s technology efforts, focusing on developing proprietary AI language models (like "Ankh") that decode protein sequences to accelerate drug design.